BCLIBrainstorm Cell Therapeutics, Inc.

$1.17
$0.03
(2.50%)
Today
Closed $1.17
$0.50
(42.73%)
After Hours
Updated: 07:59 PM EDT
Reported EarningsMay 15
Mkt Cap$8.26M
Vol2.77M
News
all
press releases
News Placeholder
BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time'
The company plans to move its shares to the OTCQB market and says the delisting won't impact its ALS research or upcoming Phase 3b trial.
Stocktwits
News Placeholder
Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours
BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.
Stocktwits
News Placeholder
News Movers: Yesterday’s Hottest News That Could Move the Needle Today
Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks
Stocktwits Contributor
<
...
1
>

Advertisement|Remove ads.